Medtronic (MDT) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic foundation and operational changes

• Renewed commitment to innovation and a performance-focused culture, with leadership changes and streamlined operations over the past five years.

• Centralized global operations and supply chain are delivering cost savings and operational resiliency.

• Portfolio management and decisive capital allocation are prioritized to ensure long-term shareholder value and financial targets.

• Implemented significant COGS efficiency programs, supplier optimization, automation, and digitalization to drive margin improvement.

• Increased capital allocation to highest growth opportunities, with $2.7B in R&D and $3.7B in dividends in FY24.

Growth drivers and innovation pipeline

• Cardiac ablation solutions, especially PulseSelect and Affera technologies, are scaling rapidly with strong safety data, high physician demand, and expanded manufacturing.

• Structural heart business is gaining traction with new products and clinical data, notably the Evolut FX+ valve, SMART trial results, and TAVR segment growth.

• Hypertension management with Symplicity is poised for major growth following CMS's national coverage analysis and new guidelines, with a billion-dollar market opportunity at just 1% penetration.

• Neuromodulation is advancing with adaptive DBS, CE marked, and a large installed base for brain-computer interface technology, driven by closed-loop and sensing technologies.

• Diabetes business is growing above average, driven by new sensor technology, expanded labeling, and a comprehensive AID & Smart MDI ecosystem.

Financial performance and margin improvement

• Consistent revenue growth over eight quarters, with high single-digit earnings growth expected in the back half of the fiscal year.

• Sequential gross margin improvement and disciplined SG&A and COGS management are supporting leveraged earnings growth.

• Active portfolio management and capital allocation, including increased focus on tuck-in M&A and share repurchases, are enhancing growth and margin profile.

• Efforts to reduce FX exposure include dynamic pricing and supply chain adjustments.

• Ongoing evaluation of portfolio to optimize shareholder value.